About Avacta
Avacta is a company based in Wetherby (United Kingdom) founded in 2003. Avacta has completed 2 acquisitions, including CorisBio and Launch Diagnostics. Avacta operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Wetherby, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avacta Group Plc
-
Annual Revenue
$141.58 K (USD)-96.04as on Dec 31, 2024
-
Net Profit
-$66.2 M (USD)-58.89as on Dec 31, 2024
-
EBITDA
-$37.79 M (USD)-45.62as on Dec 31, 2024
-
Latest Funding Round
$21.47 M (USD), Post-IPO
Oct 20, 2025
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
CorisBio
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Avacta
Avacta is a publicly listed company on the LSE with ticker symbol AVCT in UK, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Avacta
Unlock access to complete
Unlock access to complete
Funding Insights of Avacta
Investors in Avacta
Avacta has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Medical Research Council.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Medical research is conducted to advance human health improvements.
|
Locked | Locked | Locked |
Investor details for Avacta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avacta
Avacta has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CorisBio and Launch Diagnostics.
Investment portfolio details for Avacta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Rapid diagnostic tests for infectious diseases are developed and commercialized.
|
Locked | Locked | 1996 | Locked | |
|
High-quality diagnostic reagents and instruments are supplied to healthcare providers.
|
Locked | Locked | 1990 | Locked |
Complete acquisition details for Avacta
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Avacta
Detailed financials for Avacta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avacta Comparisons
Peer comparison for Avacta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avacta
Avacta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Avacta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avacta
Complete news archive for Avacta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avacta
Avacta was founded in 2003 and raised its 1st funding round 8 years after it was founded.
Avacta is headquartered in Wetherby, United Kingdom. It is registered at Wetherby, West Yorkshire, United Kingdom.
Annual revenue of Avacta is $141.58K as on Dec 31, 2024.
Avacta was founded in 2003 and is based in Wetherby, United Kingdom. Operations focus on the biotechnology sector, where immunotherapies are developed by combining Affimer biotherapeutics with precision tumor-targeted chemotherapy. Diagnostics for cancer treatment are also advanced. The lead candidate, AVA6000, represents a tumor-targeted version of doxorubicin. Activities center on oncology solutions through these integrated platforms.
Avacta's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Yes, Avacta is publicly traded on LSE under the ticker symbol AVCT.
Avacta has made 2 acquisitions, including CorisBio, and Launch Diagnostics.
Avacta has 1 investor. Key investors include Medical Research Council.
The ticker symbol of Avacta is AVCT on LSE.